WBA - Walgreens Boots Alliance, Inc.
| Previous Close | 52.89 |
| Open | 52.87 |
| Bid | 52.40 x 800 |
| Ask | 52.59 x 4000 |
| Day's Range | 52.12 - 53.05 |
| 52 Week Range | 49.31 - 86.31 |
| Volume | 3,246,332 |
| Avg. Volume | 6,471,139 |
| Market Cap | 48.065B |
| Beta (3Y Monthly) | 0.65 |
| PE Ratio (TTM) | 9.87 |
| EPS (TTM) | 5.33 |
| Earnings Date | Jun 27, 2019 |
| Forward Dividend & Yield | 1.76 (3.57%) |
| Ex-Dividend Date | 2019-05-17 |
| 1y Target Est | 57.90 |
- Motley Fool•4 hours ago
Walgreens Has an Answer for CVS's HealthHUBs
The pharmacy chain has placed a big bet on empathy.
- Markit•2 days ago
See what the IHS Markit Score report has to say about Walgreens Boots Alliance Inc.
Walgreens Boots Alliance Inc NASDAQ/NGS:WBAView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output in this company's sector is contracting Bearish sentimentShort interest | PositiveShort interest is low for WBA with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative but appears to be improving. Over the last one-month, outflows of investor capital in ETFs holding WBA totaled $272 million. However, outflows appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers’ Index (PMI) data, output in the Consumer Servicesis falling. The rate of decline is significant relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•3 days ago
Buy Kroger (KR) Stock Before Q1 Earnings as Amazon-Inspired Grocery Delivery Expands?
Overall, the first quarter has been relatively strong for retailers, so let's look at what investors should expect from Kroger to see if they should consider buying KR stock heading into its Q1 earnings release.
- American City Business Journals•3 days ago
Allow yourself some mirror time, Birchbox says
Women feel guilty about taking time for self-care, and many say their responsibility to take care of others is the reason.
- Motley Fool•4 days ago
This National Grocery Chain Will Carry CBD in 17 States
With more than 2,700 branded locations nationwide, this grocer plans to introduce topical CBD products in a third of all states.
- Zacks•5 days ago
Walgreens Boots Alliance (WBA) Dips More Than Broader Markets: What You Should Know
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $52.12, marking a -1.44% move from the previous day.
- Moody's•5 days ago
Walgreens Boots Alliance, Inc. -- Moody's announces completion of a periodic review of ratings of Walgreens Boots Alliance, Inc.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Walgreens Boots Alliance, Inc. New York, June 12, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Walgreens Boots Alliance, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
- Zacks•6 days ago
The Zacks Analyst Blog Highlights: Oracle, Eli Lilly, Mondelez, Walgreens and Southwest
The Zacks Analyst Blog Highlights: Oracle, Eli Lilly, Mondelez, Walgreens and Southwest
- Zacks•7 days ago
Top Analyst Reports for Oracle, Eli Lilly & Mondelez
Top Analyst Reports for Oracle, Eli Lilly & Mondelez
- Benzinga•7 days ago
Kroger To Introduce CBD Products In 17 States
Kroger Co (NYSE: KR ) is the latest company to introduce CBD products to its U.S. store shelves. The grocery chain's corporate affairs manager for its Michigan division, Rachel Hurst, said the company ...
- InvestorPlace•10 days ago
Fear of Amazon Creates a Bargain in FedEx Stock
Over the last year, shares of FedEx (NYSE:FDX) are down nearly 40%, opening for trade June 7 near $157 each. The reason can be summed up in one word: Amazon (NASDAQ:AMZN).Source: Shutterstock The growth of what is now the country's second-leading retailer (after Walmart (NYSE:WMT)) continues to make traders quake in their blue suede shoes. (That's your reminder that FedEx is based in Memphis.)You can buy FedEx today for less than 12 times last year's earnings and get a $2.60 per share dividend that yields 1.69%. The market cap is now $41 billion, against 2018 revenue of $65.5 billion.InvestorPlace - Stock Market News, Stock Advice & Trading TipsYou may have to wait for the market to wake up, but your patience should be rewarded. FDX Stock Is Still GrowingDespite any appearance to the contrary, FedEx continues to grow.FedEx is due to report its fourth quarter on June 25. Analysts are expecting earnings of $4.89 per share on revenue of $18.04 billion. * 7 S&P 500 Dividend Stocks to Buy at Least Yielding 3% That would put revenue for the full year at $69 billion, about $4 billion ahead of last year. It would more than cover the dividend and could spark a hike.Investors were spooked by a miss on the third quarter, earnings falling 7 cents short of estimates at $3.03 per share. CEO Fred Smith admitted they were below expectations, blaming the company's investments in network infrastructure and automation.He also could have blamed TNT Express, acquired for $4.8 billion in 2016. Integration costs on the European-based company were 21 cents per share. Matching Amazon StockBut the stock has since fallen below the level it was at after those earnings came out.The reason for that is Amazon, which continues to make headlines with things like drone delivery, its own hub airport in Kentucky, along with expansions in Rockford, Illinois, and Lakeland, Florida ,There's one thing wrong with this picture, as it relates to FedEx. That is, Amazon infrastructure serves AMZN stock, and its re-sellers. Amazon may have half the e-commerce market, but that still leaves half that's not Amazon, and there is more to delivery than e-commerce.It is more reasonable to be concerned about whether the trade war will kick FedEx out of China, or the cost of expanding ground service, or how managers might react to the end of cash bonuses.If anyone should worry about Amazon, and its knock-on effects in the delivery business, it should be the U.S. Postal Service. They just lost FedEx' SmartPost business. FedEx' expansion of Ground delivery to Sunday, matching Amazon, means it's entering a niche that had been keeping the USPS competitive.FedEx is also working closely with Amazon rivals like Walmart and Walgreens (NYSE:WBA) on next-day delivery. It's even turning Target (NYSE:TGT) stores into local shipment hubs, matching a deal Amazon recently signed with Kohl's (NYSE:KSS).Wherever Amazon innovates in delivery, FedEx does too, keeping its service competitive on behalf of all of Amazon's competitors. Economically it's a win-win. The Bottom LineBecause Amazon's recent innovations are all on the fast side of delivery, long considered FedEx' niche, the impact on FedEx stock has been twice what it was on that of rival UPS (NYSE:UPS), down 15% over the last year.Trade war fears have exacerbated that fear.As the old saying goes, when the going gets tough the tough get going. That doesn't mean the tough abandon the field. It means they compete harder. That's what FedEx is doing, and the whole economy is the beneficiary.At its current levels, given its continuing profitability and investments in the business, it's hard to see FedEx as anything but a buy for a long-term investor.Dana Blankenhorn is a financial and technology journalist. He is the author of a new environmental story, Bridget O'Flynn and the Bear, available now at the Amazon Kindle store. Write him at danablankenhorn@gmail.com or follow him on Twitter at @danablankenhorn. As of this writing he owned shares in AMZN. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 S&P 500 Dividend Stocks to Buy at Least Yielding 3% * 7 Stocks to Buy That Don't Care About Tariffs * 5 Healthcare Stocks to Pick Up From the Wreckage Compare Brokers The post Fear of Amazon Creates a Bargain in FedEx Stock appeared first on InvestorPlace.
- Insider Monkey•10 days ago
Here’s What Hedge Funds Think About Walgreens Boots Alliance Inc (WBA)
A market surge in the first quarter, spurred by easing global macroeconomic concerns and Powell's pivot ended up having a positive impact on the markets and many hedge funds as a result. The stocks of smaller companies which were especially hard hit during the fourth quarter slightly outperformed the market during the first quarter. Unfortunately, […]
- Zacks•10 days ago
Do Hemp Stocks Stand to Gain From a Weed-Liberal Illinois?
The marijuana legislation in Illinois would allow any resident of the state above the age of 21 to possess the novelty item.
- Zacks•11 days ago
Walgreens Boots Alliance (WBA) Gains But Lags Market: What You Should Know
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $50.98, marking a +0.35% move from the previous day.
- Zacks•11 days ago
Walgreens' Weak Market Trends a Woe, Strategic Deals a Boon
Walgreens Boots (WBA) is diligently trying to redress specific areas of operational weakness and enhancing its managerial skills for a better operating performance.
- Zacks•11 days ago
The Zacks Analyst Blog Highlights: General Electric, Anthem, Northrop Grumman, Walgreens and Honda
The Zacks Analyst Blog Highlights: General Electric, Anthem, Northrop Grumman, Walgreens and Honda
- Zacks•11 days ago
The Geo Group, Vista Outdoor, CVS and Walgreens Boots Alliance highlighted as Zacks Bull and Bear of the Day
The Geo Group, Vista Outdoor, CVS and Walgreens Boots Alliance highlighted as Zacks Bull and Bear of the Day
- InvestorPlace•11 days ago
3 Reasons Why Patience On CVS Health Stock Could Pay Off For Investors
In the second half of April, I wrote about the waning sentiment toward CVS Health (NYSE:CVS). On the surface, CVS stock has the necessary components to move higher. Obviously, the company is in the business of health care, which is typically not an optional endeavor for people. Second, CVS offers diverse coverage in this segment with its pharmacy benefit manager business.Source: Mike Mozart via FlickrAt the same time, CVS Health stock has components that don't favor a higher market value. One of those anchors is debt. At nearly $68 billion from its last quarterly report, that's a hefty load. Plus, health care represents a lucrative sector for companies desperate to expand beyond their boundaries. While I wouldn't characterize Amazon (NASDAQ:AMZN) as desperate, Jeff Bezos and friends are certainly willing to disrupt this segment.As a result, CVS stock has a credibility dilemma that the markets don't feel the underlying organization has effectively addressed. While I adopted the cautiously optimistic approach to the retail-pharmacy giant, shares have moved like I reasonably expected. This is a name that will require a strong stomach and significant patience, as at yesterday's $53.17 close, the shares are less than 3% off the low-end of their 52-week range.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 6 Big Dividend Stocks to Buy as Yields Plunge But if that's you, I think CVS Health stock provides an interesting platform. Here are three reasons why: Automation Can't Touch CVS StockFor many folks, especially in the rust belt of America, automation is a scary word. In fact, it's the central catalyst that has sparked political firebrand Andrew Yang's presidential campaign. Consistently, Yang argues that we're in the midst of a fourth industrial revolution that will displace millions of workers.Furthermore, the Democratic candidate points the finger at Amazon. While the e-commerce giant is the internet age's flagship success story, it also disrupted small businesses throughout the country. The fear is that CVS stock, as part of the broader retail-investment landscape, will face automation at some point.I don't think that will happen. I'll go out on a limb and say that it will never happen. This forecast bodes well for CVS Health stock, if I'm right.Let me hedge that by saying this: automation will certainly replace or substantially modify health care's administrative components. I'm not breaking new ground with this statement because it's already happening.But the medical and pharmaceutical industries involve variances. We still don't know much about the human body and its reaction to outside stimuli. That's obvious when you consider the raging opioid crisis.More critically, humans can make executive decisions that save lives. Perhaps a patient's allergy history makes a particular drug unsafe, or an obviously pregnant patient may have complications from an apparently mistaken prescription: artificial intelligence is so far unable to make such dynamic decisions. However, they're a routine part of the current pharmacy life. Politics Offer a Tailwind for CVS Health StockLike most Americans, I'm incredibly confused about the healthcare system. As a contrarian, I consider that a blessing. I really don't want to be an expert on this subject because it probably means I'm not doing too well.That said, what I do know about health care in America is that it's outrageously expensive. Becoming a medical doctor used to be a noble profession. Now, it merely seems like a pathway to riches. I love what Yang has to say about this topic: we spend the most on healthcare yet receive the worst results.You don't have to pull up wonky charts and graphs to understand the problem. As I mentioned in my last article about CVS stock, hundreds of thousands of Americans travel to Mexico each year to receive significant discounts on prescription drugs.That right there proves we have a disconnect in the system: how can patients who are only separated by arbitrary borders pay radically different drug prices? Clearly, the drugs themselves aren't that expensive to produce. Instead, we have bloated bureaucracies that have exponentially skyrocketed healthcare costs to untenable levels for many families.Fortunately, it appears Washington finally has the political will to address this escalating crisis. In the long run, I see this dynamic as a net positive for CVS stock. Theoretically, the pharmacy will gain business that's currently going off the books to Mexico. Additionally, millions of patients will have access to reasonable healthcare costs, eliminating the incentive to skimp on medication. CVS Offers a Trusted Brand NameApparently, it's in vogue to go bearish on CVS Health stock and similar names like Walgreens Boots Alliance (NASDAQ:WBA). With disruptive competitors lurking in the shadows, there doesn't seem to be much room in this segment. * The 10 Best Stocks for 2019 -- So Far But as much as I like Amazon and its ilk, I'm not sure if they can disrupt health care like they have other industries. The biggest difference I see is that health care is obviously intimate and personal. As such, people will not always make economically rational decisions here.For instance, if you're in the market for LASIK eye surgery, price isn't the deciding factor. Instead, it's skill and a very long track record of success. Your vision is an attribute that is truly priceless. You're not going to trust your eyes to a doctor with a degree from Trump University.In the same framework, CVS ranks as one of Fortune's "World's Most Admired Companies." I'm not surprised. Whenever I have medicinal needs, I run to CVS, as do millions of others. They know what they're doing. The company also hires many of the best medical professionals.Amazon? I like them for purchasing books, clothes, and electronic devices. But I'll pass on their drugs. As long as overall costs are reasonable, the track record for CVS stands above the rest.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Sell Impacted by the Mexican Tariffs * 6 Big Dividend Stocks to Buy as Yields Plunge * The 10 Biggest Announcements From Apple WWDC 2019 Compare Brokers The post 3 Reasons Why Patience On CVS Health Stock Could Pay Off For Investors appeared first on InvestorPlace.
- Zacks•12 days ago
Buy CVS Health (CVS) Stock After Optimistic Investor Day 2019?
CVS (CVS) stock jumped over 2% upon opening Tuesday morning and ended the day at $54.62, a 2.3% gain on the day. Confidence in the company???s future growth grew when it made multiple announcements regarding future earnings and projects at its investor day 2019 event.
- Zacks•12 days ago
Top Analyst Reports for General Electric, Anthem & Northrop Grumman
Top Analyst Reports for General Electric, Anthem & Northrop Grumman
- American City Business Journals•13 days ago
CVS to swap some Atlanta stores for new HealthHub concepts
CVS picked Atlanta as part of the expanded 2019 rollout based on the "combination of CVS customers and Aetna members with high rates of chronic disease."
- Yahoo Finance Video•10 days ago
Stocks soar after weak jobs report raises hopes for Fed rate cut
The U.S. economy added just 75,000 jobs in May, with unemployment holding steady at 3.6%. Joe Song, Bank of America U.S. Economist, along with Andrew Levin, Professor of Economics at Dartmouth College, join Seana Smith on 'The Ticker' to discuss.
